U.K. to keep PSE meds BTC
This article was originally published in The Tan Sheet
Executive SummaryRestrictions on sales of drugs containing ephedrine and pseudoephedrine in the U.K. have proven effective in decreasing illicit methylamphetamine production, so the Medicines and Healthcare products Regulatory Agency will not shift the products to prescription only status. In August 2007, an agency advisory panel recommended ephedrine and PSE products be sold in packages no larger than 720 mg and its Commission on Human Medicines recommended limiting sales of the drugs to pharmacy only and to one package per person (1"The Tan Sheet" Jan. 14, 2008). MHRA said July 29 in wake of the changes, meth abuse has been contained and pharmacies have seen a 25 percent drop in PSE purchases. An executive said the agency will continue to monitor sales of the meth precursors
You may also be interested in...
Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.